Tag: Hepcludex

Chronic hepatitis delta (HDV) is widely regarded as the most severe form of viral hepatitis, affecting millions worldwide. For adults with this condition and compensated liver disease, bulevirtide is used for chronic HDV infection, offering a targeted therapeutic option where few effective treatments previously existed.

Hepatitis D is the most severe form of viral hepatitis, and for decades, treatment options were severely limited. However, the approval of Hepcludex has introduced a new class of medication, known as an entry inhibitor, that effectively blocks both the hepatitis B and delta viruses from infecting healthy liver cells.